Pharmaceuticals News and Research

RSS

New operating model for speed delivery of innovative medicines

Eli Lilly and Company (NYSE: LLY) today unveiled a new operating model and announced a series of changes to speed medicines from its pipeline to patients.

15 Sep 2009

Phase III results of Lauriad presented at the 49th Annual ICAAC

BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad and anti-integrase inhibitor.

15 Sep 2009

Dominion develops and validates clinical quantitative assays for tapentadol

Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

15 Sep 2009

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

15 Sep 2009

Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.

15 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Rib-X and NIAID collaborate to develop an antibiotic treatment for N. gonorrhoeae

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that it intends to enter into a Clinical Trials Agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.

15 Sep 2009

Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful

Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma. In the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo.

15 Sep 2009

Haemacure releases financial results of third quarter 2009

Haemacure Corporation (TSX : HAE) reported today on current activities and released the financial results of its third quarter ended July 31.

15 Sep 2009

American Scientific Resources acquires Safeguard Medical's home needle destruction device patent

American Scientific Resources, Inc. (Pink Sheets: ASFX) (the Company), is excited to announce that it has acquired the intellectual property to the world's only FDA approved home needle destruction device (NDD), the Disintegrator(TM) and Disintegrator Plus(TM) (U.S. Patent No. 6,384,362 Patent Application No.: 09/500,504) (the "Device Technology").

15 Sep 2009

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

15 Sep 2009

GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

15 Sep 2009

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat.

14 Sep 2009

Phase 1 trial results of Achaogen's ACHN-490 announced at ICAAC meeting

Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.

14 Sep 2009

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

14 Sep 2009

Virtual Pharma Rep - an electronic "go green" revolutionary pharmaceutical sales product

Virtual Pharma Rep™, a new company built by pharmaceutical industry veterans, today announced their launch to market. Virtual Pharma Rep™ delivers a patent pending, virtual sales process that revolutionizes expensive pharmaceutical sales.

14 Sep 2009

ODS Health Plan selects American Imaging Management to provide diagnostic imaging services

American Imaging Management(R) (AIM), an operating subsidiary of WellPoint, Inc. (NYSE: WLP), and one of the leading imaging benefit management and technology companies with health plan clients representing over 35 million consumers, announced that it has been selected by ODS Health Plan, Inc. to provide diagnostic imaging services. Under the agreement, AIM will administer diagnostic imaging management services to ODS members in Oregon and surrounding service areas.

14 Sep 2009

Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced

Pharmos Corporation (Pink Sheets: PARS) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.

14 Sep 2009

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX® (arsenic trioxide) injection (marketed by Cephalon, Inc.) in patients with relapsed acute promyelocytic leukemia (APL).

14 Sep 2009

Altair announces positive Phase I results for AIR645 in treating asthma

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.

14 Sep 2009

Pharmaceuticals News and Research

New operating model for speed delivery of innovative medicines

Phase III results of Lauriad presented at the 49th Annual ICAAC

Dominion develops and validates clinical quantitative assays for tapentadol

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

Rib-X and NIAID collaborate to develop an antibiotic treatment for N. gonorrhoeae

Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful

Haemacure releases financial results of third quarter 2009

American Scientific Resources acquires Safeguard Medical's home needle destruction device patent

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Phase 1 trial results of Achaogen's ACHN-490 announced at ICAAC meeting

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Virtual Pharma Rep - an electronic "go green" revolutionary pharmaceutical sales product

ODS Health Plan selects American Imaging Management to provide diagnostic imaging services

Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

Altair announces positive Phase I results for AIR645 in treating asthma

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring